NEFRENE Trademark

Trademark Overview

On Friday, November 18, 2011, a trademark application was filed for NEFRENE with the United States Patent and Trademark Office. The USPTO has given the NEFRENE trademark a serial number of 85476682. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 7, 2016. This trademark is owned by Eli Lilly and Company. The NEFRENE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders; antidepressants
nefrene

General Information

Serial Number85476682
Word MarkNEFRENE
Filing DateFriday, November 18, 2011
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 7, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 11, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders; antidepressants

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 28, 2011
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events

Event DateEvent Description
Monday, March 7, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, March 7, 2016ABANDONMENT - NO USE STATEMENT FILED
Thursday, August 13, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 12, 2015EXTENSION 5 GRANTED
Friday, July 24, 2015EXTENSION 5 FILED
Friday, July 24, 2015AMENDMENT AFTER NOA NOT ENTERED
Friday, July 24, 2015TEAS EXTENSION RECEIVED
Thursday, February 12, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 11, 2015EXTENSION 4 GRANTED
Tuesday, January 20, 2015EXTENSION 4 FILED
Tuesday, January 20, 2015TEAS EXTENSION RECEIVED
Thursday, August 14, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 13, 2014EXTENSION 3 GRANTED
Friday, July 25, 2014EXTENSION 3 FILED
Friday, July 25, 2014TEAS EXTENSION RECEIVED
Wednesday, February 12, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 11, 2014EXTENSION 2 GRANTED
Friday, December 20, 2013EXTENSION 2 FILED
Friday, January 31, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 20, 2013TEAS EXTENSION RECEIVED
Saturday, July 20, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 18, 2013EXTENSION 1 GRANTED
Thursday, July 18, 2013EXTENSION 1 FILED
Thursday, July 18, 2013TEAS EXTENSION RECEIVED
Tuesday, February 5, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 11, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 11, 2012PUBLISHED FOR OPPOSITION
Wednesday, November 21, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 8, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, November 7, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 1, 2012ASSIGNED TO EXAMINER
Thursday, October 18, 2012EXAMINER'S AMENDMENT ENTERED
Thursday, October 18, 2012ASSIGNED TO LIE
Thursday, October 18, 2012NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, October 18, 2012EXAMINERS AMENDMENT E-MAILED
Thursday, October 18, 2012EXAMINERS AMENDMENT -WRITTEN
Thursday, March 15, 2012NOTIFICATION OF PRIORITY ACTION E-MAILED
Thursday, March 15, 2012PRIORITY ACTION E-MAILED
Thursday, March 15, 2012PRIORITY ACTION WRITTEN
Tuesday, March 6, 2012ASSIGNED TO EXAMINER
Monday, November 28, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, November 22, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords

nefrene disorders diseases preparations pharmaceutical inflammatory kidney liver inflammation gastrointestinal dyslipidemia